Source: Eur Respir J 2016; 48: 1230-1233



Rating:

Share or cite this content

Citations should be made in the following way:
Zuur Marlanka A., Akkerman Onno W., Davies Forsman Lina, Hu Yi, Zheng Rongdong, Bruchfeld Judith, Tiberi Simon, Migliori Giovanni Battista, Alffenaar Jan-Willem C.. Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. Eur Respir J 2016; 48: 1230-1233

Member's Comments

No comment yet.

Related content which might interest you: Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Inhaled corticosteroids in COPD: friend or foe? Source: Eur Respir J, 52 (6) 1801219; 10.1183/13993003.01219-2018 Year: 2018 Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Infection: friend or foe to the development of asthma? Source: Eur Respir J 2001; 18: 744-747 Year: 2001 Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Calcineurin inhibitors: friend and foe? Source: School Course 2012 - Lung Transplantation Year: 2012 Novel drugs against tuberculosis: a clinician's perspective Source: Eur Respir J 2015; 45: 1119-1131 Year: 2015 Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Immunotherapy: when, who and which drug? Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020 Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?}, Source: Eur Respir J 2012; 40: 1051-1053 Year: 2012 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis? Source: Eur Respir J 2016; 47: 1287-1288 Year: 2016 Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis? Source: Eur Respir J 2016; 47: 1288-1290 Year: 2016 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016